|
市場調查報告書
競爭分析：VEGF(血管内皮成長因子)とVEGF-R(血管内皮成長因子受體)促效藥與拮抗藥
Competitor Analysis VEGF and VEGF-R Agonists and Antagonists
|
競爭分析：VEGF(血管内皮成長因子)とVEGF-R(血管内皮成長因子受體)促效藥與拮抗藥 是由出版商La Merie Publishing在2009年09月所出版的。
這份英文市場調查報告書包含133 pages 價格從美金846起跳。
本研究報告提供2009年9月為止之癌症、AMD與神經保護作用治療之VEGF與其受體標的物領域之競爭分析，配合各企業之VEGF/R標的分子研究開發進程，分析整理如下。
2008年之VEGF/R拮抗藥物銷售額
VEGF-R促效藥物
眼科治療之VEGR與VEGF-R拮抗藥物
癌症治療之VEGR與VEGF-R拮抗藥物
- Avastin研究進程
- 作為VEGR與VEGF-R抑制劑之生物製劑
- 作為VEGF RTK抑制劑之小分子
- Sutent研究進程
- Nexavar研究進程
- 選擇的VEGF RTK抑制劑
- 雙標的VEGF RTK抑制劑
- 三標的VEGF RTK抑制劑
- 多重標的VEGF RTK抑制劑
- VEGF-R抑制劑受體RTK抑制之概況
企業之VEGF與VEGF-R拮抗藥與促效藥之研究開發進程
- Accelera
- ACT Biotech
- Advenchen Laboratories
- Affitech
- Allergan
- Allostera Pharma
- Alnylam Pharmaceuticals
- Amgen
- Ark Therapeutics
- AstraZeneca
- Attenuon
- Aveo Pharmaceuticals
- Bayer Schering-Pharma
- Bio-Sidus
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS) 等
Abstract
Product description
The present Competitive Intelligence Report about VEGF and VEGF-R agonists and
antagonists provides a competitor evaluation in the field of VEGF and its
receptor targeting molecules for treatment of cancer, AMD and for
neuroprotection as of September 2009. Purchase of the downloadable pdf report
includes a 6-month online access to the data of the report and any updates
since the publication date. Credentials to access the database will be sent by
e-mail and allow online work with the project data to print or export an
individual report.
The importance of tumor angiogenesis in tumor biology is now widely accepted
and has emerged as a valid therapeutic target in oncology. Vascular
endothelial growth factor (VEGF) represents a key mediator of tumor-initiated
angiogenesis and the first target of antiangiogenesis agents introduced in
clinical practice. VEGF and VEGF receptor antagonists have revolutionized
therapy of cancer which is reflected by their outstanding commercial success:
2008 sales of US$ 6.4 bln only in oncology. VEGF blockers found further use in
inhibiting or even reversing angiogenesis in neovascular (wet) age-related
macular degeneration (AMD). This market already reached US$ 1.8 bln in 2008.
Obviously, the total market size of US$ 8.2 bln for VEGF and VEGF receptor
(VEGF-R) antagonists has attracted many companies to invest in follow-up and
next generation molecules targeting VEGF and VEGF-R. The clinically validated
target provides a low risk opportunity for new technologies with proteins,
RNA, antibodies and vaccines for validation of the technologies. Multi-target
receptor tyrosine kinase (RTK) inhibitors are another possibility to further
increase the efficacy of VEGF-R antagonists by adding anti-proliferative or
anti-migration effects. In contrast to antagonism of angiogenesis, the growth
factor activity of VEGF has created a high level of interest for
neuroprotection and several approaches are in clinical evaluation.
The report includes a compilation of current active projects in research and
development of molecules targeting VEGF or VEGF receptor. In addition, the
report lists company-specific R&D pipelines of VEGF/R targeting molecules.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Table of Contents
Index
- 2008 Sales of VEGF/R Antagonists
- VEGF-R Agonists
- Cardiovascular Applications
- Neurological Applications
- VEGF and VEGF-R Antagonists in Ophthalmology
- VEGF and VEGF-R Antagonists in Oncology
- Avastin Pipeline
- Biologics as VEGF and VEGF-R Antagonists
- Small Molecules as VEGF RTK Inhibitors
- Sutent Pipeline
- Nexavar Pipeline
- Selective VEGF RTK Inhibitors
- Dual Target VEGF RTK Inhibitors
- Triple Target VEGF RTK Inhibitors
- Multi-Target VEGF RTK Inhibitors
- Overview on RTK Inhibion Profiles of VEGF-R Inhibitors
- Corporate VEGF and VEGF-R Agonists and Antagonists
- About La Merie
Corporate VEGF/R Agonist and Antagonist R&D Pipelines
- Accelera
- ACT Biotech
- Advenchen Laboratories
- Affitech
- Allergan
- Allostera Pharma
- Alnylam Pharmaceuticals
- Amgen
- Ark Therapeutics
- AstraZeneca
- Attenuon
- Aveo Pharmaceuticals
- Bayer Schering-Pharma
- Bio-Sidus
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS)
- Cephalon
- Chugai
- Circadian
- CSL
- Cyclacell Pharmaceuticals
- DxS
- Edwards Lifesciences
- Eisai
- Eli Lilly
- Epitomics
- Ethycal Oncology Sciences (EOS)
- Exelixis
- Eyetech
- Genentech
- GlaxoSmithKline (GSK)
- Jubilant Innovation
- Kringle Pharmaceuticals
- Methylgen
- Millennium
- Molecular Partner
- Nanogen Biopharmaceuticals
- Neovacs
- NeuroNova
- Neurotech
- Novartis
- Onyx Pharmaceuticals
- Opko
- OSI Pharmaceuticals
- Oxford BioMedica
- Pepscan Systems
- Pfizer
- Pieris
- PTC Therapeutics
- Regeneron Pharmaceuticals
- Roche
- Sangamo Biosciences
- Sanofi-aventis
- Schering
- SibTech
- Sirna Therapeutics
- Sopherion Therapeutics
- Symphony Evolution
- Takeda Pharmaceutical
- Targa Therapeutics
- Tekmira
- Telik
- Tigris Pharmaceuticals
- Toolgen
- Trophogen
- VasGene
- ZymoGenetics
|
